AU672888B2 - Carbostyril derivatives as matrix metalloproteinases inhibitors - Google Patents

Carbostyril derivatives as matrix metalloproteinases inhibitors Download PDF

Info

Publication number
AU672888B2
AU672888B2 AU62637/94A AU6263794A AU672888B2 AU 672888 B2 AU672888 B2 AU 672888B2 AU 62637/94 A AU62637/94 A AU 62637/94A AU 6263794 A AU6263794 A AU 6263794A AU 672888 B2 AU672888 B2 AU 672888B2
Authority
AU
Australia
Prior art keywords
group
compound
reaction
dihydrocarbostyril
lower alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU62637/94A
Other languages
English (en)
Other versions
AU6263794A (en
Inventor
Takeshi Imaoka
Masaaki Motoyama
Makoto Sakamoto
Hideki Takasu
Yoshihito Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of AU6263794A publication Critical patent/AU6263794A/en
Application granted granted Critical
Publication of AU672888B2 publication Critical patent/AU672888B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU62637/94A 1993-03-18 1994-03-17 Carbostyril derivatives as matrix metalloproteinases inhibitors Ceased AU672888B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP5826493 1993-03-18
JP5-58264 1993-03-18
JP25687393 1993-10-14
JP5-256873 1993-10-14
PCT/JP1994/000434 WO1994021612A1 (en) 1993-03-18 1994-03-17 Carbostyril derivatives as matrix metalloproteinases inhibitors

Publications (2)

Publication Number Publication Date
AU6263794A AU6263794A (en) 1994-10-11
AU672888B2 true AU672888B2 (en) 1996-10-17

Family

ID=26399315

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62637/94A Ceased AU672888B2 (en) 1993-03-18 1994-03-17 Carbostyril derivatives as matrix metalloproteinases inhibitors

Country Status (7)

Country Link
EP (1) EP0641323A1 (ref)
KR (1) KR950704257A (ref)
CN (1) CN1105799A (ref)
AU (1) AU672888B2 (ref)
CA (1) CA2136108A1 (ref)
TW (1) TW290541B (ref)
WO (1) WO1994021612A1 (ref)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
AR004214A1 (es) * 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
JP2000500761A (ja) 1995-11-23 2000-01-25 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
WO1997024117A1 (en) * 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
PT891187E (pt) * 1996-04-04 2002-06-28 Hoffmann La Roche Utilizacao de derivados de tetrahidro-beta-carbolinos como agentes antimestaticos
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
NZ333923A (en) 1996-09-10 2000-11-24 British Biotech Pharm Cytostatic hydroxamic acid derivatives for inhibiting proliferation of tumour cells
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
ATE360014T1 (de) 2001-06-15 2007-05-15 Vicuron Pharm Inc Bicyclische pyrrolidinverbindungen
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
ATE373502T1 (de) 2003-07-30 2007-10-15 Otsuka Pharma Co Ltd Carbostyril-derivative zur beschleunigten speichelabsonderung
CN108285469B (zh) * 2018-03-15 2020-07-24 遵义医学院 一种抗菌类喹诺酮衍生物及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB9107368D0 (en) * 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
CN1105799A (zh) 1995-07-26
TW290541B (ref) 1996-11-11
CA2136108A1 (en) 1994-09-29
EP0641323A1 (en) 1995-03-08
WO1994021612A1 (en) 1994-09-29
AU6263794A (en) 1994-10-11
KR950704257A (ko) 1995-11-17

Similar Documents

Publication Publication Date Title
US4215064A (en) Phosphobetaines
US4380637A (en) Imidazoline phosphobetaines
AU616824B2 (en) Condensed benzene derivatives for use in treatment of cerebral disorders
DE69503904T2 (de) Phosphinsaeurederivate mit metallopeptidase inhibtorischer wirkung
US6156768A (en) Alpha- and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors
EP0320118B1 (en) Peptides with collagenase inhibiting activity
US6933305B2 (en) Amide compounds and use thereof
DE69827786T2 (de) Condensierte pyridazine derivate,deren herstellung und verwendung
AU714025B2 (en) Sulfonamide derivatives
US5512576A (en) 2-substituted 1,2,5,-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
AU6263794A (en) Carbostyril derivatives as matrix metalloproteinases inhibitors
US5594006A (en) Carbostyril derivatives as matrix metalloproteinases inhibitors
BG105788A (bg) Сулфамато хидроксамова киселина като металопротеазен инхибитор
JPH0656663A (ja) Ｎ−複素環アルキル置換フェニル誘導体の投与による破骨細胞媒介骨吸収の新規な抑制方法
US6936602B1 (en) Benzazepine derivatives, process for the preparation of the same and uses thereof
WO1991009851A1 (fr) Derive d'oxyde de 1,3,2-dioxathiolane
US5556909A (en) Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives and compositions and method of use thereof
EP4562001A1 (en) Substituted pyridine derivatives as sarm1 inhibitors
DE69531296T2 (de) Anti-tumor verbindungen, welche einen zyklopentaquinazolin zyklus enthalten
DE69524064T2 (de) Indan-2-mercaptoacetylamid disulfidderivate als enkephalinase inhibitoren
DE3881755T2 (de) Pyrrolidin-Derivate.
US7427634B2 (en) Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them
JPH05502233A (ja) 薬理学的に活性なアミドカルボキシレート誘導体
US4735962A (en) 7-thiabicycloheptane substituted diamide and its congener prostaglandin analogs
JPH0881443A (ja) 細胞外マトリックス金属プロテアーゼ阻害剤